Notice NOT-DC-22-007 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-086 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis. The R21 FOA is intended to encourage exploratory projects that are at an early conceptual stage feasibility study (inception through preliminary development) to demonstrate the core functional capabilities of the proposed approach. The proposed projects may involve considerable risk and should be aimed at producing breakthroughs in microbial-based cancer therapy, imaging, or diagnosis. This funding opportunity is part of broader NCI-sponsored research on microbial-based cancer therapy.

Funding Opportunity PAR-22-085 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis. This funding opportunity is part of broader NCI-sponsored research on microbial-based cancer therapy. (link to OCCAM)

Experience with gene expression analyses, computational biology, genomics and bioinformatics desired. Knowledge of current technological developments/trends…
From Medical College of Wisconsin - Fri, 18 Feb 2022 03:13:55 GMT - View all Milwaukee, WI jobs

Notice NOT-OD-22-049 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-055 from the NIH Guide for Grants and Contracts

Notice NOT-HS-22-010 from the NIH Guide for Grants and Contracts

Notice NOT-TR-22-018 from the NIH Guide for Grants and Contracts

Notice NOT-NS-22-001 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-23-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites R61/R33 applications that address health equity, drug costs, and access to new therapeutics or repurposed drugs for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Successful applications will seek to identify preferences for pharmacological treatment among racial and ethnic minority people living with AD/ADRD, assess whether cost barriers to pharmacological care exist for racial and ethnic minority people living with AD/ADRD, and quantify expenditures and health- related quality of life (HRQoL) among people interested in receiving novel or repurposed drugs for AD/ADRD.This FOA will support a study development phase (R61) to conduct rigorous stakeholder engagement with racial and ethnic minority groups to identify, measure, and assess the demand for new and repurposed drugs, and if successful, grantees will transition to an R33 phase for implementation of rigorous modeling of costs and health-related quality of life and dissemination of model findings.

£33,272-£41,709 per annum: Wellcome Sanger Institute: The Opportunity: The Cellular Genetics Programme is seeking two computational postdoctoral fellows to support the Haniffa Group. The Programme is f... Cambridge, Cambridgeshire (GB)

Collaborate with various clinical and research project teams focused on the analysis and use of genomic and RNA sequence data, such that project goals and…
From Medical College of Wisconsin - Thu, 17 Feb 2022 15:09:58 GMT - View all Milwaukee, WI jobs

Funding Opportunity RFA-OD-22-005 from the NIH Guide for Grants and Contracts. The goals of this RADx-UP Funding Opportunity Announcement (FOA) are to conduct social, ethical, and behavioral implications (SEBI) research to understand and reduce barriers to COVID-19 testing, as well as COVID-19 disparities that arise from barriers to testing among underserved and vulnerable populations. The funding for this initiative is provided from the American Rescue Plan Act of 2021, PL 117-2.

Funding Opportunity RFA-OD-22-006 from the NIH Guide for Grants and Contracts. The goals of this funding opportunity announcement (FOA) are to implement and rigorously evaluate SARS-CoV-2 rapid testing strategies in communities experiencing COVID-19 health disparities. These two-year Rapid Testing Research Projects will evaluate (1) rapid testing interventions to prevent and control COVID-19 transmission among underserved and vulnerable populations and (2) partnership-driven research to implement and evaluate rapid testing and reduce COVID-19 disparities. The funding for this program is provided from the American Rescue Plan Act of 2021, PL 117-2.

Funding Opportunity RFA-RM-22-008 from the NIH Guide for Grants and Contracts. The purpose of the FIRST Cohort is to transform culture at NIH-funded extramural institutions by building a self-reinforcing community of scientists committed to diversity and inclusive excellence (defined below). Implementing and sustaining cultures of inclusive excellence within the program has the potential to be transformational for biomedical research at the awardee institutions and beyond. This community will be built through recruitment of individuals who: are competitive for an advertised research tenure-track or equivalent faculty position (positions must be at the Assistant Professor (or equivalent) level), meet the criteria for NIH-defined Early Stage Investigators, and have demonstrated a strong commitment to promoting diversity and inclusive excellence.

It is expected that the candidate will be proficient in project design, development of computable solutions, application and modification of open source scripts…
From Medical College of Wisconsin - Wed, 16 Feb 2022 21:10:31 GMT - View all Milwaukee, WI jobs

Notice NOT-NS-22-080 from the NIH Guide for Grants and Contracts

Notice NOT-NS-22-077 from the NIH Guide for Grants and Contracts

Notice NOT-DA-21-079 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DE-23-004 from the NIH Guide for Grants and Contracts. This initiative is intended to accelerate research using animal models and precision medicine approaches to develop in utero treatments of congenital dental and craniofacial disorders. The long-term goal is to lay the groundwork for delivery of in utero treatments in human.